Project Grant R43HL174220
Award Date 9/15/25
Completion Date 8/30/26
Dollars Obligated $458K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Massachusetts, USA
Similar Awards
- This Project Grant award, totaling $499,585.00, was provided by the National Heart Lung and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to The University of Texas Health Science Center at Tyler. The project aims to develop a novel therapeutic strategy called "Two-Target Fibrinolytic Therapy" (T2FT) to increase the efficacy of empyema treatment. The research involves preclinical testing and optimization of a combination therapy using alteplase (ALT), a docking site...
- This Project Grant award from the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research federal grant program (CFDA 93.837), provides $464,229 to Limax Biosciences Inc. to advance the development of their HEMOMAX biodegradable hydrogel sealant for use in vascular surgery. The key objectives are to: (1) conduct comprehensive bench performance testing, including sterilization validation and endotoxin assessment, and (2) evaluate the safety and efficacy of HEMOMAX in a...
- This Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $434,658 to Oakland University to conduct research on the intracellular function of the platelet protein TREM-like transcript-1 (TLT-1). The research aims to characterize the phosphorylation sites of TLT-1 and decipher the intracellular cues that regulate its trafficking in platelets. The...
- The U.S. Department of Health and Human Services, National Institutes of Health (NIH) awarded a $155,857 Project Grant under the Trans-NIH Research Support (CFDA 93.310) program to Signablok, Inc. in Massachusetts. The funding supports the development of a novel medical countermeasure to mitigate potentially lethal acute radiation syndrome (ARS). The project aims to create a well-tolerable and effective first-in-class therapeutic that can be administered at least 24 hours post-radiation exposure...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research program (CFDA 93.837) provides $288,986 to Biotherapeutics, Inc., a biotechnology company in Blacksburg, VA. The grant supports the development of a novel oral immunoregulatory therapeutic for the treatment of asthma. The key objectives are to: 1) Determine the safety profile and pharmacokinetics of the new therapeutic in rats, and 2) Characterize the therapeutic...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $496,255 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to Vivita Technologies, Inc. (Davis, CA) to validate its patented SPEAR Platform™ technology for developing unfixed, immune-compatible, and regenerative xenogeneic biomaterials for transcatheter heart valve replacements. The project aims to produce BARE™ patches derived from porcine pericardium that can avoid immune rejection, integrate with...
- The U.S. Department of Health and Human Services (HHS) National Institutes of Health (NIH) awarded a $499,882 Project Grant under the Trans-NIH Research Support program (CFDA 93.310) to SNJ Pharma Inc. in Torrance, CA. The grant supports the development of a novel plasmin-independent thrombolytic enzyme, recombinant high-temperature requirement A1 (rHTRA1), as a potential treatment for pulmonary embolism (PE). The proposed research aims to further evaluate the therapeutic efficacy of rHTRA1 in a...
- This $1,488,899 Project Grant award was provided by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) to Young Therapeutics LLC, a pharmaceutical research and development company based in Pennsylvania. The funding supports the advanced development and validation of two proprietary compounds, YT-002 and YT-004, which target specific protein kinases to preserve myocardial tissue and cardiac function following myocardial infarction. The research aims to...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), provides $656,988 to the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University to enable new therapies for bacterial pneumonia. The objective of this 5-year project is to develop a therapeutic strategy that can replace a failed component of the macrophage lung injury response and allow healing in patients with...
- This Project Grant award for $355,935 from the National Heart, Lung, and Blood Institute (NHLBI) under the Cardiovascular Diseases Research federal grant program (CFDA 93.837) supports the development of a novel, oral immunoregulatory therapeutic for the treatment of asthma. The primary objectives are to characterize the therapeutic efficacy and dosing regimen of the compound in mouse models of asthma, and to evaluate its ability to modulate immune function and suppress inflammation in human...